A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis

While rare, serious adverse effects including euglycemic diabetic ketoacidosis (EDKA) have been associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) use. We present an interesting case of SGLT2i-induced EDKA occurring two years after initiation of therapy. Most patients with EDKA recove...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Shiavax J, Kumar, Kaushik, Saleh, Nahar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643074/
https://www.ncbi.nlm.nih.gov/pubmed/36381906
http://dx.doi.org/10.7759/cureus.30106
_version_ 1784826448684515328
author Rao, Shiavax J
Kumar, Kaushik
Saleh, Nahar
author_facet Rao, Shiavax J
Kumar, Kaushik
Saleh, Nahar
author_sort Rao, Shiavax J
collection PubMed
description While rare, serious adverse effects including euglycemic diabetic ketoacidosis (EDKA) have been associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) use. We present an interesting case of SGLT2i-induced EDKA occurring two years after initiation of therapy. Most patients with EDKA recover with prompt recognition and treatment. Patient education about identifying early signs remains a cornerstone of early identification and response to SGLT2i-induced EDKA.
format Online
Article
Text
id pubmed-9643074
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-96430742022-11-14 A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis Rao, Shiavax J Kumar, Kaushik Saleh, Nahar Cureus Cardiology While rare, serious adverse effects including euglycemic diabetic ketoacidosis (EDKA) have been associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) use. We present an interesting case of SGLT2i-induced EDKA occurring two years after initiation of therapy. Most patients with EDKA recover with prompt recognition and treatment. Patient education about identifying early signs remains a cornerstone of early identification and response to SGLT2i-induced EDKA. Cureus 2022-10-09 /pmc/articles/PMC9643074/ /pubmed/36381906 http://dx.doi.org/10.7759/cureus.30106 Text en Copyright © 2022, Rao et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Rao, Shiavax J
Kumar, Kaushik
Saleh, Nahar
A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
title A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
title_full A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
title_fullStr A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
title_full_unstemmed A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
title_short A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
title_sort case of sglt2 inhibitor-induced euglycemic diabetic ketoacidosis
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643074/
https://www.ncbi.nlm.nih.gov/pubmed/36381906
http://dx.doi.org/10.7759/cureus.30106
work_keys_str_mv AT raoshiavaxj acaseofsglt2inhibitorinducedeuglycemicdiabeticketoacidosis
AT kumarkaushik acaseofsglt2inhibitorinducedeuglycemicdiabeticketoacidosis
AT salehnahar acaseofsglt2inhibitorinducedeuglycemicdiabeticketoacidosis
AT raoshiavaxj caseofsglt2inhibitorinducedeuglycemicdiabeticketoacidosis
AT kumarkaushik caseofsglt2inhibitorinducedeuglycemicdiabeticketoacidosis
AT salehnahar caseofsglt2inhibitorinducedeuglycemicdiabeticketoacidosis

Ejemplares similares